Are drug-eluting stents the future of SFA treatment?
Drug-eluting stent (DES) technology was developed to prevent early thrombosis and late luminal loss to potentially improve long-term patency rates. Although favorable DES results have recently become available with the Zilver PTX and STRIDES studies, the high price of DES is a major drawback for this technology to become the golden standard for peripheral endovascular therapy in de novo femoro-popliteal (FP) lesions. Nevertheless, DES has the potential to make the difference and to establish itself as an important treatment option in patients presenting with TASC C&D FP lesions who are at high-risk for surgery and for the treatment of in-stent restenosis, where until now, no valuable treatment option has proven to be beneficial.
Bosiers
M
M
Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium. marc.bosiers@telenet.be
Deloose
K
K
Keirse
K
K
Verbist
J
J
Peeters
P
P
D017130:Angioplasty / Q000009:adverse effects / Q000191:economics / Q000295:instrumentation*; D001157:Arterial Occlusive Diseases / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D003251:Constriction, Pathologic; D003362:Cost-Benefit Analysis; D054855:Drug-Eluting Stents / Q000191:economics; D005263:Femoral Artery / Q000503:physiopathology; D006801:Humans; D011150:Popliteal Artery / Q000503:physiopathology; D011474:Prosthesis Design; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency